TriSalus Life Sciences Inc. (TLSI)
NASDAQ · Healthcare
TriSalus Life Sciences Inc. EBITDA 2022–2025
TriSalus Life Sciences Inc. annual/quarterly ebitda history and growth rate from 2022 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- TriSalus Life Sciences Inc. ebitda for the quarter ending March 31, 2026 was -8.3 M, a 15.64% increase year-over-year.
- TriSalus Life Sciences Inc. ebitda for the twelve months ending March 31, 2026 was -36.9 M.
- TriSalus Life Sciences Inc. annual ebitda for 2025 was -26.3 M, a 25.69% decrease from 2024.
- TriSalus Life Sciences Inc. annual ebitda for 2024 was -35.4 M, a 34.15% decrease from 2023.
- TriSalus Life Sciences Inc. annual ebitda for 2023 was -53.8 M, a 49.25% increase from 2022.
- TriSalus Life Sciences Inc. annual ebitda for 2022 was -36.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
TriSalus Life Sciences Inc. EBITDA — FAQ
TriSalus Life Sciences Inc. (TLSI) ebitda over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TLSI's ebitda history?
The chart and table above show TriSalus Life Sciences Inc.'s ebitda by year and by quarter, including the growth rate.